DK2278509T3 - Fremgangsmåder, systemer og software til identificering af funktionelle biomolekyler - Google Patents
Fremgangsmåder, systemer og software til identificering af funktionelle biomolekyler Download PDFInfo
- Publication number
- DK2278509T3 DK2278509T3 DK10181000.0T DK10181000T DK2278509T3 DK 2278509 T3 DK2278509 T3 DK 2278509T3 DK 10181000 T DK10181000 T DK 10181000T DK 2278509 T3 DK2278509 T3 DK 2278509T3
- Authority
- DK
- Denmark
- Prior art keywords
- population
- elements
- selecting
- identifying
- sequence
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 381
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 195
- 229920001184 polypeptide Polymers 0.000 claims description 194
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 194
- 108091033319 polynucleotide Proteins 0.000 claims description 94
- 102000040430 polynucleotide Human genes 0.000 claims description 94
- 239000002157 polynucleotide Substances 0.000 claims description 93
- 229920001222 biopolymer Polymers 0.000 claims description 57
- 238000012216 screening Methods 0.000 claims description 47
- 238000004590 computer program Methods 0.000 claims description 27
- 230000002194 synthesizing effect Effects 0.000 claims description 10
- 238000002955 isolation Methods 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 description 265
- 102000004169 proteins and genes Human genes 0.000 description 215
- 235000018102 proteins Nutrition 0.000 description 211
- 230000000694 effects Effects 0.000 description 160
- 235000001014 amino acid Nutrition 0.000 description 101
- 150000001413 amino acids Chemical class 0.000 description 72
- 230000006870 function Effects 0.000 description 63
- 239000011159 matrix material Substances 0.000 description 61
- 150000007523 nucleic acids Chemical class 0.000 description 61
- 230000006798 recombination Effects 0.000 description 54
- 238000005215 recombination Methods 0.000 description 54
- 102000039446 nucleic acids Human genes 0.000 description 53
- 108020004707 nucleic acids Proteins 0.000 description 53
- 125000000539 amino acid group Chemical group 0.000 description 50
- 238000004422 calculation algorithm Methods 0.000 description 47
- 230000008569 process Effects 0.000 description 46
- 238000013459 approach Methods 0.000 description 40
- 238000013528 artificial neural network Methods 0.000 description 39
- 108091034117 Oligonucleotide Proteins 0.000 description 38
- 239000000047 product Substances 0.000 description 38
- 108020004414 DNA Proteins 0.000 description 37
- 125000003275 alpha amino acid group Chemical group 0.000 description 37
- 230000000875 corresponding effect Effects 0.000 description 34
- 239000000243 solution Substances 0.000 description 34
- 238000012628 principal component regression Methods 0.000 description 33
- 238000004458 analytical method Methods 0.000 description 30
- 238000012549 training Methods 0.000 description 27
- 230000002068 genetic effect Effects 0.000 description 25
- 230000035772 mutation Effects 0.000 description 25
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 21
- 238000003556 assay Methods 0.000 description 21
- 238000005457 optimization Methods 0.000 description 20
- 238000006467 substitution reaction Methods 0.000 description 20
- 238000000338 in vitro Methods 0.000 description 19
- 238000002703 mutagenesis Methods 0.000 description 19
- 231100000350 mutagenesis Toxicity 0.000 description 19
- 239000002773 nucleotide Substances 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 18
- 238000000126 in silico method Methods 0.000 description 18
- 238000013461 design Methods 0.000 description 17
- 125000003729 nucleotide group Chemical group 0.000 description 17
- 230000014509 gene expression Effects 0.000 description 16
- 230000001404 mediated effect Effects 0.000 description 15
- 238000001727 in vivo Methods 0.000 description 14
- 230000036961 partial effect Effects 0.000 description 14
- 239000002609 medium Substances 0.000 description 13
- 239000002253 acid Substances 0.000 description 12
- 150000007513 acids Chemical class 0.000 description 12
- 108091093088 Amplicon Proteins 0.000 description 11
- 238000013400 design of experiment Methods 0.000 description 11
- 238000009826 distribution Methods 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 230000003993 interaction Effects 0.000 description 10
- 230000009897 systematic effect Effects 0.000 description 10
- 239000013598 vector Substances 0.000 description 10
- 239000012620 biological material Substances 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- 229920000642 polymer Polymers 0.000 description 9
- 238000011160 research Methods 0.000 description 9
- 238000005070 sampling Methods 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 230000009286 beneficial effect Effects 0.000 description 8
- 230000001419 dependent effect Effects 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 238000010276 construction Methods 0.000 description 7
- 238000006062 fragmentation reaction Methods 0.000 description 7
- 238000012163 sequencing technique Methods 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 6
- 230000003044 adaptive effect Effects 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 230000029087 digestion Effects 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 238000013467 fragmentation Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 108020004705 Codon Proteins 0.000 description 5
- 102000053602 DNA Human genes 0.000 description 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 230000000996 additive effect Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 238000004364 calculation method Methods 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000010238 partial least squares regression Methods 0.000 description 5
- 238000003909 pattern recognition Methods 0.000 description 5
- 238000000638 solvent extraction Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 238000004891 communication Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000002596 correlated effect Effects 0.000 description 4
- 238000002790 cross-validation Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 238000004088 simulation Methods 0.000 description 4
- 238000002741 site-directed mutagenesis Methods 0.000 description 4
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 108091005461 Nucleic proteins Proteins 0.000 description 3
- 108091093037 Peptide nucleic acid Proteins 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 210000004102 animal cell Anatomy 0.000 description 3
- 238000012219 cassette mutagenesis Methods 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000010429 evolutionary process Effects 0.000 description 3
- 238000013537 high throughput screening Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 238000012417 linear regression Methods 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 238000000491 multivariate analysis Methods 0.000 description 3
- 238000002515 oligonucleotide synthesis Methods 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 238000000513 principal component analysis Methods 0.000 description 3
- 230000001850 reproductive effect Effects 0.000 description 3
- 238000010845 search algorithm Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 108700005078 Synthetic Genes Proteins 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- 238000003052 fractional factorial design Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 2
- 238000012203 high throughput assay Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000010365 information processing Effects 0.000 description 2
- 238000002898 library design Methods 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 239000004973 liquid crystal related substance Substances 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000001902 propagating effect Effects 0.000 description 2
- 230000004952 protein activity Effects 0.000 description 2
- 230000004853 protein function Effects 0.000 description 2
- 238000002708 random mutagenesis Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000012706 support-vector machine Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- VGONTNSXDCQUGY-RRKCRQDMSA-N 2'-deoxyinosine Chemical group C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC2=O)=C2N=C1 VGONTNSXDCQUGY-RRKCRQDMSA-N 0.000 description 1
- CXRFDZFCGOPDTD-UHFFFAOYSA-M Cetrimide Chemical compound [Br-].CCCCCCCCCCCCCC[N+](C)(C)C CXRFDZFCGOPDTD-UHFFFAOYSA-M 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 241001074710 Eucalyptus populnea Species 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 108091005973 GFP derivatives Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 238000012218 Kunkel's method Methods 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 238000007476 Maximum Likelihood Methods 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000000342 Monte Carlo simulation Methods 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000283283 Orcinus orca Species 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 102000000395 SH3 domains Human genes 0.000 description 1
- 108050008861 SH3 domains Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- ZVNYJIZDIRKMBF-UHFFFAOYSA-N Vesnarinone Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)N1CCN(C=2C=C3CCC(=O)NC3=CC=2)CC1 ZVNYJIZDIRKMBF-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 238000003766 bioinformatics method Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 238000005460 biophysical method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000000837 carbohydrate group Chemical group 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000010370 cell cloning Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000009402 cross-breeding Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 238000007418 data mining Methods 0.000 description 1
- 238000003066 decision tree Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 230000008713 feedback mechanism Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000003055 full factorial design Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000012188 high-throughput screening assay Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000009399 inbreeding Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 238000010801 machine learning Methods 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000005055 memory storage Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000012269 metabolic engineering Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000000302 molecular modelling Methods 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- -1 nucleotide triphosphates Chemical class 0.000 description 1
- 230000005257 nucleotidylation Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000000596 photon cross correlation spectroscopy Methods 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920001690 polydopamine Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 238000002818 protein evolution Methods 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 238000013515 script Methods 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 238000009394 selective breeding Methods 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000012772 sequence design Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 108020001568 subdomains Proteins 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001550 time effect Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 239000006163 transport media Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/30—Detection of binding sites or motifs
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/50—Mutagenesis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
- G16B35/20—Screening of libraries
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/20—Supervised data analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/60—In silico combinatorial chemistry
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
Landscapes
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Theoretical Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biophysics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Evolutionary Biology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Library & Information Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Data Mining & Analysis (AREA)
- Biochemistry (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Public Health (AREA)
- Bioethics (AREA)
- Databases & Information Systems (AREA)
- Artificial Intelligence (AREA)
- Epidemiology (AREA)
- Evolutionary Computation (AREA)
- Software Systems (AREA)
- Medicinal Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Computing Systems (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Information Retrieval, Db Structures And Fs Structures Therefor (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Management, Administration, Business Operations System, And Electronic Commerce (AREA)
Claims (16)
1. Fremgangsmåde til identificering af elementer afen population af polypep-tid-sekvensvarianter, der er mest egnede til kunstig evolution, hvilken fremgangsmåde omfatter: (a) at udvælge eller screene elementerne af en population af polypeptid-sekvensvarianter for to eller flere ønskede strukturelle og/eller funktionelle egenskaber med henblik på at udarbejde et datasæt; (b) at identificere en Pareto-front i datasættet; (c) at udvælge et eller flere elementer langs med Pareto-fronten, hvorved der identificeres de elementer af populationen af polypeptid-sekvensvarianter, der er mest egnede til kunstig evolution; og (d) at syntetisere elementerne udvalgt i trin (c).
2. Fremgangsmåde til identificering af elementer af en population af polynu-kleotid-sekvensvarianter, der er mest egnede til kunstig evolution, hvilken fremgangsmåde omfatter: (a) at udvælge eller screene elementerne af en population af polynukleotid-sekvensvarianter for to eller flere strukturelle og/eller funktionelle egenskaber med henblik på at udarbejde et datasæt; (b) at identificere en Pareto-front i datasættet; (c) at udvælge et eller flere elementer langs med Pareto-fronten, hvorved der identificeres de elementer af populationen af polynukleotid-sekvensvarianter, der er mest egnede til kunstig evolution; og (d) at syntetisere elementerne udvalgt i trin (c).
3. Fremgangsmåde ifølge krav 1 eller 2, hvor trin (c) omfatter: (i) at kalkulere en vægtet sum af de to eller flere ønskede strukturelle og/eller funktionelle egenskaber for mindst nogle af elementerne langs med Pareto-fronten; og (ii) at udvælge mindst et element omfattende en højere vægtet sum end andre elementer langs med Pareto-fronten.
4. Fremgangsmåde ifølge krav 1 eller 2, hvor trin (c) omfatter: (i) at rangordne det ene eller de flere elementer langs med Pareto-fronten efter relativ isolation i sekvensrummet; og (ii) at udvælge mindst et element, som rangerer højere end andre elementer langs med Pareto-fronten.
5. Fremgangsmåde ifølge krav 1, hvilken fremgangsmåde omfatter: (a) at fremstille en population af polypeptid-sekvensvarianter; (b) at udvælge eller screene elementerne af populationen af polypeptid-sekvensvarianter for to eller flere strukturelle og/eller funktionelle egenskaber med henblik på at udarbejde et datasæt; (c) at identificere en Pareto-front i datasættet; (d) at udvælge et eller flere elementer langs med Pareto-fronten, hvorved der identificeres de elementer af populationen af polypeptid-sekvensvarianter, der er mest egnede til kunstig evolution; og (e) at syntetisere elementerne udvalgt i trin (d).
6. Fremgangsmåde ifølge krav 2, hvilken fremgangsmåde omfatter: (a) at fremstille en population af polynukleotid-sekvensvarianter; (b) at udvælge eller screene elementerne af populationen af polynukleotid-sekvensvarianter for to eller flere strukturelle og/eller funktionelle egenskaber med henblik på at udarbejde et datasæt; (c) at identificere en Pareto-front i datasættet; (d) at udvælge et eller flere elementer langs med Pareto-fronten, hvorved der identificeres de elementer af populationen af polynukleotid-sekvensvarianter, der er mest egnede til kunstig evolution; og (e) at syntetisere elementerne udvalgt i trin (d).
7. Fremgangsmåde ifølge krav 5 eller 6, hvor trin (d) omfatter: (i) at kalkulere en vægtet sum af de to eller flere ønskede strukturelle og/eller funktionelle egenskaber for mindst nogle af elementerne langs med Pareto- fronten; og (ii) at udvælge mindst et element omfattende en højere vægtet sum end andre elementer langs med Pareto-fronten.
8. Fremgangsmåde ifølge krav 5 eller 6, hvor trin (d) omfatter: (i) at rangordne det ene eller de flere elementer langs med Pareto-fronten efter relativ isolation i sekvensrummet; og (ii) at udvælge mindst et element, som rangerer højere end andre elementer langs med Pareto-fronten.
9. Fremgangsmåde ifølge krav 4 eller 8, hvor rangordningen omfatter at opdele Pareto-fronten i hyperboxe og fortrinsvis at udvælge elementer fra mindre befolkede hyperboxe.
10. Fremgangsmåde ifølge et af kravene 1, 2, 5 eller 6, hvor de to eller de flere strukturelle og/eller funktionelle egenskaber omfatter begrænsninger, værdier, der detaljerer afstanden fra at opnå begrænsninger, et samlet antal af opfyldte begrænsninger, et relativt antal af opfyldte begrænsninger, og/eller konkurrerende eller ikke-konkurrerende strukturelle og/eller funktionelle egenskaber af populationen af biopolymere sekvensvarianter.
11. Fremgangsmåde ifølge et af kravene 1, 2, 5 eller 6, hvor de to eller de flere strukturelle og/eller funktionelle egenskaber er ortogonale i forhold til hinanden.
12. Fremgangsmåde ifølge et af kravene 1,2, 5 eller 6, hvor udvælgelsen af det ene eller de flere elementer langs med Pareto-fronten omfatter at anvende en niching-teknik.
13. Computerprogramprodukt til identificering af elementer af en population af polypeptid-sekvensvarianter, der er mest egnede til kunstig evolution, omfattende et computerlæsbart medium, som har logiske instruktioner for: (a) at udvælge eller screene elementerne af en population af polypeptid-sekvensvarianter for to eller flere ønskede strukturelle og/eller funktionelle egenskaber med henblik på at udarbejde et datasæt; (b) at identificere en Pareto-front i datasættet; og (c) at udvælge et eller flere elementer langs med Pareto-fronten, hvorved der identificeres de elementer af populationen af polypeptid-sekvensvarianter, der er mest egnede til kunstig evolution.
14. Computerprogramprodukt til identificering af elementer af en population af polypeptid-sekvensvarianter, der er mest egnede til kunstig evolution, omfattende et computerlæsbart medium, som har logiske instruktioner for: (a) at udvælge eller screene elementerne af en population af polynukleotid-sekvensvarianter for to eller flere strukturelle og/eller funktionelle egenskaber med henblik på at udarbejde et datasæt; (b) at identificere en Pareto-front i datasættet; og (c) at udvælge et eller flere elementer langs med Pareto-fronten, hvorved der identificeres de elementer af populationen af polynukleotid-sekvensvarianter, der er mest egnede til kunstig evolution.
15. Computersystem til identificering af elementer af en population af po-lypeptid-sekvensvarianter, der er mest egnede til kunstig evolution, omfattende: (i) en computer med en database, som er i stand til at lagre datasættet ifølge krav 1; og (ii) systemsoftware, som indeholder logiske instruktioner for: (a) at udvælge eller screene elementerne af en population af polypeptid-sekvensvarianter for to eller flere ønskede strukturelle og/eller funktionelle egenskaber med henblik på at udarbejde et datasæt; (b) at identificere en Pareto-front i datasættet; og (c) at udvælge et eller flere elementer langs med Pareto-fronten, hvorved der identificeres de elementer af populationen af polypeptid-sekvensvarianter, der er mest egnede til kunstig evolution.
16. Computersystem til identificering af elementer afen population af polynukleotid-sekvensvarianter, der er mest egnede til kunstig evolution, omfattende: (i) en computer med en database, som er i stand til at lagre datasættet ifølge krav 2; og (ii) systemsoftware, som indeholder logiske instruktioner for: (a) at udvælge eller screene elementerne af en population af polynukleotid-sekvensvarianter for to eller flere strukturelle og/eller funktionelle egenskaber med henblik på at udarbejde et datasæt; (b) at identificere en Pareto-front i datasættet; og (c) at udvælge et eller flere elementer langs med Pareto-fronten, hvorved der identificeres de elementer af populationen af polynukleotid-sekvensvarianter, der er mest egnede til kunstig evolution.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36098202P | 2002-03-01 | 2002-03-01 | |
| EP03743748.0A EP1493027B1 (en) | 2002-03-01 | 2003-03-03 | Methods, systems, and software for identifying functional bio-molecules |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2278509T3 true DK2278509T3 (da) | 2014-12-15 |
Family
ID=27789053
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10181159.4T DK2315145T3 (da) | 2002-03-01 | 2003-03-03 | Fremgangsmåder, systemer, og software til identifikation af funktionelle biomolekyler |
| DK03743748.0T DK1493027T3 (da) | 2002-03-01 | 2003-03-03 | Fremgangsmåder, systemer og software til identificering af funktionelle biomolekyler |
| DK10181000.0T DK2278509T3 (da) | 2002-03-01 | 2003-03-03 | Fremgangsmåder, systemer og software til identificering af funktionelle biomolekyler |
| DK10181057.0T DK2390803T3 (da) | 2002-03-01 | 2003-03-03 | Fremgangsmåder, systemer og software til identificering af funktionelle biomolekyler |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10181159.4T DK2315145T3 (da) | 2002-03-01 | 2003-03-03 | Fremgangsmåder, systemer, og software til identifikation af funktionelle biomolekyler |
| DK03743748.0T DK1493027T3 (da) | 2002-03-01 | 2003-03-03 | Fremgangsmåder, systemer og software til identificering af funktionelle biomolekyler |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10181057.0T DK2390803T3 (da) | 2002-03-01 | 2003-03-03 | Fremgangsmåder, systemer og software til identificering af funktionelle biomolekyler |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7783428B2 (da) |
| EP (4) | EP1493027B1 (da) |
| JP (2) | JP5319865B2 (da) |
| AU (1) | AU2003216507A1 (da) |
| DK (4) | DK2315145T3 (da) |
| ES (1) | ES2564570T3 (da) |
| HU (1) | HUE028524T2 (da) |
| SI (1) | SI2315145T1 (da) |
| WO (1) | WO2003075129A2 (da) |
Families Citing this family (129)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050084907A1 (en) | 2002-03-01 | 2005-04-21 | Maxygen, Inc. | Methods, systems, and software for identifying functional biomolecules |
| EP1493027B1 (en) | 2002-03-01 | 2014-10-15 | Codexis Mayflower Holdings, LLC | Methods, systems, and software for identifying functional bio-molecules |
| US7747391B2 (en) * | 2002-03-01 | 2010-06-29 | Maxygen, Inc. | Methods, systems, and software for identifying functional biomolecules |
| KR100858081B1 (ko) * | 2003-02-14 | 2008-09-10 | 삼성전자주식회사 | 유전정보 코딩장치 및 방법 |
| WO2004079539A2 (en) * | 2003-03-04 | 2004-09-16 | Carnegie Mellon University | System and method for generating and using a pooled knowledge base |
| WO2005008936A2 (en) * | 2003-07-11 | 2005-01-27 | Computer Associates Think, Inc. | Method and apparatus for plan generation |
| EP1660970A4 (en) * | 2003-08-01 | 2007-02-14 | Dna Twopointo Inc | SYSTEMS AND METHODS FOR BIOPOLYMER TECHNOLOGY |
| US8005620B2 (en) * | 2003-08-01 | 2011-08-23 | Dna Twopointo Inc. | Systems and methods for biopolymer engineering |
| DE10343690A1 (de) * | 2003-09-18 | 2005-04-21 | Caesar Stiftung | Verfahren zur Bestimmung optimierter Oligomere |
| WO2006019892A2 (en) * | 2004-07-14 | 2006-02-23 | Invitrogen Corporation | Methods and systems for in silico experimental design and for providing a biotechnology product to a customer |
| JP2008526259A (ja) * | 2005-01-13 | 2008-07-24 | コドン デバイシズ インコーポレイテッド | 蛋白質デザインのための組成物及び方法 |
| KR101516823B1 (ko) | 2006-03-17 | 2015-05-07 | 바이오겐 아이덱 엠에이 인코포레이티드 | 안정화된 폴리펩티드 조성물 |
| US20090118130A1 (en) | 2007-02-12 | 2009-05-07 | Codexis, Inc. | Structure-activity relationships |
| JP2008271825A (ja) * | 2007-04-27 | 2008-11-13 | Hitachi Plant Technologies Ltd | 培養槽に関する制御因子決定方法及びこれを用いた物質生産方法 |
| JP5003499B2 (ja) | 2008-01-14 | 2012-08-15 | 富士通株式会社 | 多目的最適化設計支援装置、方法、及びプログラム |
| US8768871B2 (en) * | 2008-02-12 | 2014-07-01 | Codexis, Inc. | Method of generating an optimized, diverse population of variants |
| US8504498B2 (en) * | 2008-02-12 | 2013-08-06 | Codexis, Inc. | Method of generating an optimized, diverse population of variants |
| WO2009149218A2 (en) * | 2008-06-03 | 2009-12-10 | Codon Devices, Inc. | Novel proteins and methods of designing and using same |
| US8510151B2 (en) | 2008-07-23 | 2013-08-13 | Accenture Global Services Limited | Integrated production loss management |
| EP2401369B1 (en) | 2009-02-26 | 2014-12-24 | Codexis, Inc. | Beta-glucosidase variant enzymes and related polynucleotides |
| WO2010107644A2 (en) | 2009-03-17 | 2010-09-23 | Codexis, Inc. | Variant endoglucanases and related polynucleotides |
| CA2762616C (en) | 2009-06-16 | 2015-08-18 | Codexis, Inc. | Beta-glucosidase variant enzymes and related polynucleotides |
| WO2011028708A1 (en) | 2009-09-04 | 2011-03-10 | Codexis, Inc. | Variant cbh2 cellulases and related polynucleotides |
| RU2012126131A (ru) | 2009-11-25 | 2013-12-27 | Кодексис, Инк. | РЕКОМБИНАНТНЫЕ ВАРИАНТЫ β-ГЛЮКОЗИДАЗЫ ДЛЯ ПРОДУКЦИИ РАСТВОРИМЫХ САХАРОВ ИЗ ЦЕЛЛЮЛОЗНОЙ БИОМАССЫ |
| WO2011066187A1 (en) | 2009-11-25 | 2011-06-03 | Codexis, Inc. | Recombinant thermoascus aurantiacus beta-glucosidase variants for production of fermentable sugars from cellulosic biomass |
| EP2569426A4 (en) | 2010-05-14 | 2013-10-09 | Codexis Inc | ZELLBIOHYDROLASE VARIANTS |
| WO2012024662A2 (en) | 2010-08-20 | 2012-02-23 | Codexis, Inc. | Expression constructs comprising fungal promoters |
| ES2623288T3 (es) | 2010-08-20 | 2017-07-10 | Codexis, Inc. | Uso de proteínas de la familia de glicólido hidrolasa 61 en el procesamiento de celulosa |
| WO2012135110A1 (en) | 2011-03-30 | 2012-10-04 | Codexis, Inc. | Pentose fermentation by a recombinant microorganism |
| EP2726651B1 (en) | 2011-06-28 | 2018-11-07 | Codexis, Inc. | Protein variant generation by region shuffling |
| WO2013003219A1 (en) | 2011-06-30 | 2013-01-03 | Codexis, Inc. | Pentose fermentation by a recombinant microorganism |
| DK2748317T3 (da) | 2011-08-22 | 2017-07-17 | Codexis Inc | GH61-glycosidhydrolase-proteinvarianter og cofaktorer der forstærker GH61-aktivitet |
| BR112014003740A2 (pt) | 2011-08-23 | 2018-08-14 | Codexis Inc | variantes da celobiohidrolase |
| EP2760997A4 (en) | 2011-09-30 | 2015-02-11 | Codexis Inc | MUSHROOM PROTEASE |
| BR112014015030A2 (pt) | 2011-12-20 | 2017-06-13 | Codexis Inc | variantes da endoflucanase 1b (eg1b) |
| US20140357727A1 (en) | 2011-12-20 | 2014-12-04 | Codexis, Inc. | Fatty alcohol forming acyl reductase (far) variants and methods of use |
| WO2013159055A1 (en) | 2012-04-20 | 2013-10-24 | Codexis, Inc. | Production of fatty alcohols from engineered microorganisms |
| US8980578B2 (en) | 2012-06-11 | 2015-03-17 | Codexis, Inc. | Fungal beta-xylosidase variants |
| US9650655B2 (en) | 2012-07-20 | 2017-05-16 | Codexis, Inc. | Production of fatty alcohols from engineered microorganisms |
| BR112015011466A8 (pt) | 2012-11-20 | 2018-05-02 | Codexis Inc | Célula hospedeira fúngica recombinante, constructo de ácido nucleico recombinante, sequência de polpeptídeo isolada, e, métodos para produzir um produto de fermentação e pelo menos um produto final a partir de pelo menos um substrato celulósico |
| WO2014093070A1 (en) | 2012-12-14 | 2014-06-19 | Codexis, Inc. | Modified native beta-ketoacyl-acp synthases and engineered microorganisms |
| EP4414988A3 (en) * | 2013-01-31 | 2024-11-06 | Codexis, Inc. | Methods, systems, and software for identifying bio-molecules using models of multiplicative form |
| KR102218930B1 (ko) | 2013-04-18 | 2021-02-23 | 코덱시스, 인코포레이티드 | 조작된 페닐알라닌 암모니아 리아제 폴리펩티드 |
| US10696964B2 (en) | 2013-09-27 | 2020-06-30 | Codexis, Inc. | Automated screening of enzyme variants |
| JP6643987B2 (ja) | 2013-11-13 | 2020-02-12 | コデクシス， インコーポレイテッド | ケトン化合物およびアミン化合物の還元的アミノ化のための操作されたイミンレダクターゼおよび方法 |
| KR101400947B1 (ko) * | 2013-12-27 | 2014-05-29 | 한국과학기술정보연구원 | 변이 유전체 시퀀스 예측 방법, 장치 및 변이 유전체 시퀀스 예측 프로그램을 저장하는 저장매체 |
| WO2015161019A1 (en) | 2014-04-16 | 2015-10-22 | Codexis, Inc. | Engineered tyrosine ammonia lyase |
| US9708587B2 (en) | 2014-07-09 | 2017-07-18 | Codexis, Inc. | P450-BM3 variants with improved activity |
| DK3224354T3 (da) | 2014-11-25 | 2021-03-01 | Codexis Inc | Manipulerede iminreductaser og fremgangsmåder til den reduktive aminering af keton- og aminforbindelser |
| FI3237621T3 (fi) | 2014-12-22 | 2023-06-01 | Codexis Inc | Ihmisen alfa-galaktosidaasivariantteja |
| WO2016130412A1 (en) | 2015-02-10 | 2016-08-18 | Codexis, Inc. | Ketoreductase polypeptides for the synthesis of chiral compounds |
| AU2016258091B2 (en) | 2015-05-07 | 2020-10-01 | Codexis, Inc. | Penicillin-G acylases |
| EP3294757B1 (en) | 2015-05-13 | 2023-12-27 | Synlogic Operating Company, Inc. | Bacteria engineered to treat a disease or disorder |
| WO2016210384A2 (en) | 2015-06-25 | 2016-12-29 | Synlogic, Inc. | Bacteria engineered to treat metabolic diseases |
| CA2991195C (en) | 2015-07-07 | 2021-06-29 | Codexis, Inc. | Novel p450-bm3 variants with improved activity |
| WO2017123592A1 (en) | 2016-01-11 | 2017-07-20 | Synlogic, Inc. | Bacteria engineered to treat disorders associated with bile salts |
| WO2017123418A1 (en) | 2016-01-11 | 2017-07-20 | Synlogic, Inc. | Bacteria engineered to treat metabolic diseases |
| WO2017123676A1 (en) | 2016-01-11 | 2017-07-20 | Synlogic, Inc. | Recombinant bacteria engineered to treat diseases and disorders associated with amino acid metabolism and methods of use thereof |
| WO2017139708A1 (en) | 2016-02-10 | 2017-08-17 | Synlogic, Inc. | Bacteria engineered to treat nonalcoholic steatohepatitis (nash) |
| SG11201808957UA (en) | 2016-05-05 | 2018-11-29 | Codexis Inc | Penicillin-g acylases |
| IL263448B2 (en) | 2016-06-09 | 2023-10-01 | Codexis Inc | Biological catalysts and methods for hydroxylation of chemical compounds |
| JP2019517801A (ja) | 2016-06-15 | 2019-06-27 | コデクシス， インコーポレイテッド | 操作されたβ−グルコシダーゼおよびグルコシル化方法 |
| WO2018038906A1 (en) | 2016-08-26 | 2018-03-01 | Codexis, Inc. | Engineered imine reductases and methods for the reductive amination of ketone and amine compounds |
| MX2019008096A (es) | 2017-01-05 | 2019-09-04 | Codexis Inc | Penicilina g acilasas. |
| EP3568782A1 (en) * | 2017-01-13 | 2019-11-20 | Massachusetts Institute Of Technology | Machine learning based antibody design |
| KR102905512B1 (ko) | 2017-02-03 | 2025-12-29 | 테이트 앤드 라일 솔루션스 유에스에이 엘엘씨 | 조작된 글리코실트랜스퍼라제 및 스테비올 글리코시드 글루코실화 방법 |
| AU2018217495B2 (en) | 2017-02-13 | 2021-03-04 | Codexis, Inc. | Engineered phenylalanine ammonia lyase polypeptides |
| CA3061133A1 (en) | 2017-04-27 | 2018-11-01 | Codexis, Inc. | Ketoreductase polypeptides and polynucleotides |
| MX2019013289A (es) | 2017-05-08 | 2020-01-15 | Codexis Inc | Variantes de ligasa modificadas geneticamente. |
| CN111032682B (zh) | 2017-06-14 | 2024-04-12 | 科德克希思公司 | 用于工业生物催化的工程化转氨酶多肽 |
| US11643642B2 (en) | 2017-06-27 | 2023-05-09 | Codexis, Inc. | Penicillin-g acylases |
| CN111417724A (zh) | 2017-06-30 | 2020-07-14 | 科德克希思公司 | T7 rna聚合酶变体 |
| US10793841B2 (en) | 2017-06-30 | 2020-10-06 | Codexis, Inc. | T7 RNA polymerase variants |
| CN111246942B (zh) * | 2017-10-10 | 2026-03-20 | 梅塔博隆股份有限公司 | 使用非靶向质谱平台检测的生化物质的分析验证的简化方法 |
| SG11202003094PA (en) | 2017-11-07 | 2020-05-28 | Codexis Inc | Transglutaminase variants |
| WO2019118557A1 (en) | 2017-12-13 | 2019-06-20 | Codexis, Inc. | Carboxyesterase polypeptides for amide coupling |
| US10900055B2 (en) | 2018-06-12 | 2021-01-26 | Codexis, Inc. | Engineered tyrosine ammonia lyase |
| MX2021000326A (es) | 2018-07-09 | 2021-03-25 | Codexis Inc | Desoxirribosa-fosfato aldolasas modificadas geneticamente. |
| IL279886B2 (en) | 2018-07-09 | 2026-03-01 | Codexis Inc | Engineered variant purine nucleoside phosphorylase enzymes |
| CA3103514A1 (en) | 2018-07-09 | 2020-01-16 | Codexis, Inc. | Engineered galactose oxidase variant enzymes |
| EP3821026A4 (en) | 2018-07-09 | 2022-06-01 | Codexis, Inc. | MANIPULATED ENZYME VARIANTS OF PHOSPHOPENTOMUTASE |
| SG11202012136YA (en) | 2018-07-09 | 2021-01-28 | Codexis Inc | Engineered pantothenate kinase variant enzymes |
| JP2021531749A (ja) | 2018-07-12 | 2021-11-25 | コデクシス， インコーポレイテッド | 操作されたフェニルアラニンアンモニアリアーゼポリペプチド |
| IL280302B2 (en) | 2018-07-30 | 2025-09-01 | Codexis Inc | Engineered glycosyltransferases and methods for glycosylation of steviol glycoside |
| EP3837692A4 (en) * | 2018-08-15 | 2022-07-06 | Zymergen, Inc. | BIOREACHABLES PREDICTION TOOL WITH BIOLOGICAL SEQUENCES SELECTION |
| US11853851B2 (en) | 2018-10-03 | 2023-12-26 | Camelot Uk Bidco Limited | Systems and methods for training and employing machine learning models for unique string generation and prediction |
| CN113195085B (zh) | 2018-10-11 | 2024-04-19 | 伯克利之光生命科技公司 | 用于识别优化蛋白产生的系统和方法以及其试剂盒 |
| IL282456B2 (en) | 2018-10-29 | 2025-07-01 | Codexis Inc | Engineered dna polymerase variants |
| EP3664095A1 (en) * | 2018-12-06 | 2020-06-10 | Universidade Nova de Lisboa | Method and computer program for determining or altering a cofactor specificity of a target enzyme |
| SG11202105668PA (en) | 2018-12-14 | 2021-06-29 | Codexis Inc | Engineered tyrosine ammonia lyase |
| SG11202106348QA (en) | 2018-12-20 | 2021-07-29 | Codexis Inc | Human alpha-galactosidase variants |
| JP2022518212A (ja) | 2019-01-15 | 2022-03-14 | コデクシス， インコーポレイテッド | 操作されたトランスアミナーゼポリペプチド |
| EP3963058A4 (en) | 2019-05-01 | 2024-01-03 | Codexis, Inc. | MODIFIED GLUCOSE DEHYDROGENASES AND PROCESSES FOR THE REDUCTIVE AMINATION OF KETONE AND AMINO COMPOUNDS |
| JP7584804B2 (ja) | 2019-05-01 | 2024-11-18 | コデクシス， インコーポレイテッド | 操作されたイミンレダクターゼ、ならびにケトンおよびアミン化合物の還元的アミノ化のための方法 |
| KR20240033101A (ko) * | 2019-05-02 | 2024-03-12 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 합성 단백질 안정성을 증가시키기 위한 시스템 및 방법 |
| US10515715B1 (en) | 2019-06-25 | 2019-12-24 | Colgate-Palmolive Company | Systems and methods for evaluating compositions |
| JP7726528B2 (ja) | 2019-07-02 | 2025-08-20 | コデクシス， インコーポレイテッド | 操作された酢酸キナーゼバリアント酵素 |
| WO2021003132A1 (en) | 2019-07-02 | 2021-01-07 | Codexis, Inc. | Engineered sucrose phosphorylase variant enzymes |
| CA3148478A1 (en) * | 2019-08-22 | 2021-02-25 | Karl Anton Grothe KREMLING | Methods and systems for assessing genetic variants |
| EP4501403A3 (en) | 2019-08-30 | 2025-05-14 | Société des Produits Nestlé S.A. | Engineered lipase variants |
| WO2021050348A1 (en) | 2019-09-12 | 2021-03-18 | Codexis, Inc. | Peroxidase activity towards 10-acetyl-3,7-dihydroxyphenoxazine |
| WO2021108209A1 (en) | 2019-11-26 | 2021-06-03 | Codexis, Inc. | Biocatalysts and methods for hydroxylation of chemical compounds |
| KR20220129547A (ko) | 2019-12-20 | 2022-09-23 | 코덱시스, 인코포레이티드 | 조작된 산성 알파-글루코시다제 변이체 |
| WO2021158686A1 (en) | 2020-02-04 | 2021-08-12 | Codexis, Inc. | Engineered leucine decarboxylases |
| CN115427557A (zh) | 2020-04-10 | 2022-12-02 | 科德克希思公司 | 工程化转氨酶多肽 |
| US12603153B2 (en) * | 2020-08-12 | 2026-04-14 | Thaumachron LLC | De novo generation of high diversity proteins in silico with selective affinity and cross-reactivity minimization |
| EP4204554A4 (en) | 2020-08-28 | 2024-08-21 | Codexis, Inc. | MODIFIED PROTEASE VARIANTS |
| MX2023002421A (es) | 2020-08-28 | 2023-05-18 | Codexis Inc | Variantes de amilasa modificadas geneticamente. |
| WO2022133289A2 (en) | 2020-12-18 | 2022-06-23 | Codexis, Inc. | Engineered uridine phosphorylase variant enzymes |
| US11913036B2 (en) | 2021-04-02 | 2024-02-27 | Codexis, Inc. | Engineered acetate kinase variant enzymes |
| WO2022212828A1 (en) | 2021-04-02 | 2022-10-06 | Codexis, Inc. | Engineered guanylate kinase variant enzymes |
| US12180483B2 (en) | 2021-04-02 | 2024-12-31 | Codexis, Inc. | Engineered cyclic GMP-AMP synthase (cGAS) variant enzymes |
| CN117120600A (zh) | 2021-04-02 | 2023-11-24 | 科德克希思公司 | 工程化腺苷酸激酶变体酶 |
| TW202313969A (zh) | 2021-05-21 | 2023-04-01 | 美商克迪科思股份有限公司 | 經工程化的甲硫胺酸γ解離酶變異體 |
| CN115688537A (zh) * | 2021-07-22 | 2023-02-03 | 科思创德国股份有限公司 | 确定化合物配方中各成分的目标比例的方法和装置 |
| WO2023047557A1 (ja) * | 2021-09-27 | 2023-03-30 | 国立大学法人東北大学 | 機械学習によるタンパク質設計法 |
| KR20240100491A (ko) | 2021-10-15 | 2024-07-01 | 코덱시스, 인코포레이티드 | 조작된 말단 데옥시뉴클레오티딜 트랜스퍼라제 변이체 |
| EP4416278A4 (en) | 2021-10-15 | 2026-01-14 | Codexis Inc | MODIFIED DNA POLYMERASE VARIANTS |
| CN118475692A (zh) | 2021-11-01 | 2024-08-09 | 森蒂斯生物公司 | 工程化亮氨酸脱羧酶 |
| WO2023245171A1 (en) | 2022-06-17 | 2023-12-21 | Synlogic Operating Company, Inc. | Bacteria engineered to treat diseases associated with bile acid metabolism and methods of use thereof |
| WO2023245168A1 (en) | 2022-06-17 | 2023-12-21 | Synlogic Operating Company, Inc. | Bacteria engineered to treat diseases associated with bile acid metabolism and methods of use thereof |
| CA3260276A1 (en) | 2022-06-23 | 2023-12-28 | Michael James | Genetically modified recombinant bacteria for treating diseases associated with methionine metabolism and associated methods of use |
| EP4573553A1 (en) | 2022-08-15 | 2025-06-25 | ABSCI Corporation | Quantitative affinity activity specific cell enrichment |
| CN116072227B (zh) | 2023-03-07 | 2023-06-20 | 中国海洋大学 | 海洋营养成分生物合成途径挖掘方法、装置、设备和介质 |
| JPWO2024236722A1 (da) * | 2023-05-16 | 2024-11-21 | ||
| WO2025144700A1 (en) | 2023-12-27 | 2025-07-03 | Absci Corporation | Nanobody library screening using bacterial surface display |
| WO2025199112A2 (en) | 2024-03-19 | 2025-09-25 | General Biological Corporation | Bio-based production of succinic acid using vibrio natriegens |
| WO2025235589A1 (en) | 2024-05-08 | 2025-11-13 | Codexis, Inc. | Dna polymerase variants |
| WO2026053219A1 (en) | 2024-09-08 | 2026-03-12 | Yeda Research And Development Co. Ltd. | Polyphenol oxidase, an amino acid transporter, and a transgenic cell, tissue, and organism comprising same |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5426039A (en) | 1993-09-08 | 1995-06-20 | Bio-Rad Laboratories, Inc. | Direct molecular cloning of primer extended DNA containing an alkane diol |
| US6117679A (en) | 1994-02-17 | 2000-09-12 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| US5834252A (en) | 1995-04-18 | 1998-11-10 | Glaxo Group Limited | End-complementary polymerase reaction |
| US6335160B1 (en) | 1995-02-17 | 2002-01-01 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| US6171820B1 (en) | 1995-12-07 | 2001-01-09 | Diversa Corporation | Saturation mutagenesis in directed evolution |
| US6537776B1 (en) | 1999-06-14 | 2003-03-25 | Diversa Corporation | Synthetic ligation reassembly in directed evolution |
| US6326204B1 (en) | 1997-01-17 | 2001-12-04 | Maxygen, Inc. | Evolution of whole cells and organisms by recursive sequence recombination |
| EP1717322B1 (en) | 1997-01-17 | 2012-07-18 | Codexis Mayflower Holdings, LLC | Evolution of whole cells and organisms by recursive sequence recombination |
| EP0973940B1 (en) | 1997-03-18 | 2008-07-02 | Novozymes A/S | An in vitro method for the construction of a dna library |
| JP4263248B2 (ja) | 1997-03-18 | 2009-05-13 | ノボザイムス アクティーゼルスカブ | Ｄｎａのシャッフリングによるライブラリーの作成方法 |
| US5948653A (en) | 1997-03-21 | 1999-09-07 | Pati; Sushma | Sequence alterations using homologous recombination |
| US6153410A (en) | 1997-03-25 | 2000-11-28 | California Institute Of Technology | Recombination of polynucleotide sequences using random or defined primers |
| AU1124499A (en) | 1997-10-28 | 1999-05-17 | Maxygen, Inc. | Human papillomavirus vectors |
| WO1999023107A1 (en) | 1997-10-31 | 1999-05-14 | Maxygen, Incorporated | Modification of virus tropism and host range by viral genome shuffling |
| DK1036198T3 (da) | 1997-12-08 | 2013-01-02 | California Inst Of Techn | Fremgangsmåde til fremstilling af polynukleotid- og polypeptidsekvenser |
| CA2320958A1 (en) | 1998-02-11 | 1999-08-19 | Maxygen, Inc. | Antigen library immunization |
| MXPA00007893A (es) | 1998-02-11 | 2002-10-23 | Maxygen Inc | Direccion de vectores de vacunas geneticas. |
| US5914245A (en) | 1998-04-20 | 1999-06-22 | Kairos Scientific Inc. | Solid phase enzyme kinetics screening in microcolonies |
| ATE547532T1 (de) | 1998-06-29 | 2012-03-15 | Bristol Myers Squibb Co | Verfahren zur erzeugung von hochgradig diversen bibliotheken |
| FR2782323B1 (fr) | 1998-08-12 | 2002-01-11 | Proteus | Procede de production in vitro de sequences polynucleotidiques recombinees, banques de sequences et sequences ainsi obtenues |
| CA2331335A1 (en) | 1998-09-29 | 2000-04-06 | Maxygen, Inc. | Shuffling of codon altered genes |
| CA2345203A1 (en) | 1998-10-07 | 2000-04-13 | Maxygen Inc. | Dna shuffling to produce nucleic acids for mycotoxin detoxification |
| US20020048772A1 (en) * | 2000-02-10 | 2002-04-25 | Dahiyat Bassil I. | Protein design automation for protein libraries |
| US7315786B2 (en) | 1998-10-16 | 2008-01-01 | Xencor | Protein design automation for protein libraries |
| WO2000042559A1 (en) | 1999-01-18 | 2000-07-20 | Maxygen, Inc. | Methods of populating data structures for use in evolutionary simulations |
| US6436675B1 (en) | 1999-09-28 | 2002-08-20 | Maxygen, Inc. | Use of codon-varied oligonucleotide synthesis for synthetic shuffling |
| EP1130093A1 (en) | 1999-01-19 | 2001-09-05 | Maxygen, Inc. | Oligonucleotide mediated nucleic acid recombination |
| WO2001029211A2 (en) | 1999-10-19 | 2001-04-26 | Enchira Biotechnology Corporation | Method for directed evolution by random chimeragenesis on transient templates |
| WO2001029212A1 (en) | 1999-10-19 | 2001-04-26 | Enchira Biotechnology Corporation | Methods for chimeragenesis of whole genomes or large polynucleotides |
| WO2001059066A2 (en) * | 2000-02-10 | 2001-08-16 | Xencor, Inc. | Protein design automation for protein libraries |
| AU2001238397A1 (en) | 2000-02-17 | 2001-08-27 | California Institute Of Technology | Computationally targeted evolutionary design |
| US20010051855A1 (en) | 2000-02-17 | 2001-12-13 | California Institute Of Technology | Computationally targeted evolutionary design |
| WO2001064864A2 (en) | 2000-02-28 | 2001-09-07 | Maxygen, Inc. | Single-stranded nucleic acid template-mediated recombination and nucleic acid fragment isolation |
| EP1272967A2 (en) | 2000-03-30 | 2003-01-08 | Maxygen, Inc. | In silico cross-over site selection |
| US20030032059A1 (en) | 2000-05-23 | 2003-02-13 | Zhen-Gang Wang | Gene recombination and hybrid protein development |
| EP1283877A2 (en) * | 2000-05-23 | 2003-02-19 | California Institute Of Technology | Gene recombination and hybrid protein development |
| US20020155460A1 (en) * | 2000-10-10 | 2002-10-24 | Genencor International Inc. | Information rich libraries |
| US7747391B2 (en) * | 2002-03-01 | 2010-06-29 | Maxygen, Inc. | Methods, systems, and software for identifying functional biomolecules |
| US20050084907A1 (en) | 2002-03-01 | 2005-04-21 | Maxygen, Inc. | Methods, systems, and software for identifying functional biomolecules |
| EP1493027B1 (en) | 2002-03-01 | 2014-10-15 | Codexis Mayflower Holdings, LLC | Methods, systems, and software for identifying functional bio-molecules |
-
2003
- 2003-03-03 EP EP03743748.0A patent/EP1493027B1/en not_active Expired - Lifetime
- 2003-03-03 US US10/379,378 patent/US7783428B2/en not_active Expired - Lifetime
- 2003-03-03 EP EP10181057.0A patent/EP2390803B1/en not_active Expired - Lifetime
- 2003-03-03 ES ES10181159.4T patent/ES2564570T3/es not_active Expired - Lifetime
- 2003-03-03 DK DK10181159.4T patent/DK2315145T3/da active
- 2003-03-03 EP EP10181000.0A patent/EP2278509B1/en not_active Expired - Lifetime
- 2003-03-03 AU AU2003216507A patent/AU2003216507A1/en not_active Abandoned
- 2003-03-03 WO PCT/US2003/006551 patent/WO2003075129A2/en not_active Ceased
- 2003-03-03 DK DK03743748.0T patent/DK1493027T3/da active
- 2003-03-03 DK DK10181000.0T patent/DK2278509T3/da active
- 2003-03-03 JP JP2003573522A patent/JP5319865B2/ja not_active Expired - Lifetime
- 2003-03-03 HU HUE10181159A patent/HUE028524T2/en unknown
- 2003-03-03 SI SI200332463T patent/SI2315145T1/sl unknown
- 2003-03-03 EP EP10181159.4A patent/EP2315145B1/en not_active Expired - Lifetime
- 2003-03-03 DK DK10181057.0T patent/DK2390803T3/da active
-
2009
- 2009-05-21 JP JP2009123638A patent/JP2009277235A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| ES2564570T3 (es) | 2016-03-23 |
| EP1493027A2 (en) | 2005-01-05 |
| JP2009277235A (ja) | 2009-11-26 |
| EP2278509B1 (en) | 2014-11-19 |
| DK2390803T3 (da) | 2014-01-27 |
| DK1493027T3 (da) | 2014-11-17 |
| EP2390803B1 (en) | 2013-11-20 |
| SI2315145T1 (sl) | 2016-03-31 |
| EP1493027B1 (en) | 2014-10-15 |
| JP2005519384A (ja) | 2005-06-30 |
| EP2315145B1 (en) | 2015-11-25 |
| US7783428B2 (en) | 2010-08-24 |
| WO2003075129A3 (en) | 2003-12-31 |
| WO2003075129A2 (en) | 2003-09-12 |
| US20040072245A1 (en) | 2004-04-15 |
| EP2315145A1 (en) | 2011-04-27 |
| EP2278509A1 (en) | 2011-01-26 |
| EP2390803A1 (en) | 2011-11-30 |
| AU2003216507A8 (en) | 2003-09-16 |
| AU2003216507A1 (en) | 2003-09-16 |
| HUE028524T2 (en) | 2016-12-28 |
| EP1493027A4 (en) | 2006-03-29 |
| JP5319865B2 (ja) | 2013-10-16 |
| DK2315145T3 (da) | 2016-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2278509T3 (da) | Fremgangsmåder, systemer og software til identificering af funktionelle biomolekyler | |
| US7747391B2 (en) | Methods, systems, and software for identifying functional biomolecules | |
| US20220238179A1 (en) | Methods and systems for engineering biomolecules | |
| EP2250594B1 (en) | Method of generating an optimized, diverse population of variants | |
| EP2250595B1 (en) | Method of selecting an optimized diverse population of variants | |
| US8224580B2 (en) | Optimization of crossover points for directed evolution | |
| DK2250594T3 (da) | Fremgangsmåde til generering af en optimeret, forskelligartet population af varianter |